Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Merck's non-statin cholesterol drug, enlicitide decanoate, is being tested for the treatment of hyperlipidemia, a condition that causes elevated buildup of fat in the blood vessels and can lead to ...

Sanofi said on Tuesday it had stopped supplying Praluent, a popular cholesterol drug jointly developed by the French ...

Can a drug that lowers “bad” cholesterol — and also raises the so-called “good cholesterol,” HDL — help to prevent ...

Facing an end to Keytruda's market exclusivity, the company will cut $3 billion in costs that it plans to redeploy in support ...

WinRevair’s Phase 3 HYPERION trial was stopped early for efficacy, with positive top-line results announced in the month ...

Merck’s non-statin cholesterol drug, enlicitide decanoate, is being tested for the treatment of hyperlipidemia, a condition that causes elevated buildup of fat in the blood vessels and can lead ...

Federal regulators have rejected Merck & Co.'s new combination cholesterol drug, which includes a generic version of the mega-blockbuster Lipitor — at least for now.It's unclear how long the ...

Merck & Co. said its oral PCSK9 inhibitor candidate enlicitide hit its key goals in a pair of late-stage studies in adults with high cholesterol. Merck, which is evaluating the safety and efficacy ...

Merck & Co., Inc. (NYSE:MRK) on Monday shared topline results from the first two of three Phase 3 clinical trials evaluating the safety and efficacy of enlicitide decanoate, an investigational ...

A large study of a new type of cholesterol medicine from Merck & Co Inc found it cut the risk of heart attack and death by a modest 9 percent, while causing a build up of the drug in fat tissue ...

(Reuters) -Merck's oral cholesterol pill succeeded in two late-stage studies, marking a win for the drugmaker as it focuses on the development of growth drivers beyond its cancer drugs and vaccines.